C. Rauch

Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients

S. Khier, D. Fabre, Jean-Marie Martinez, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II

X. Nicolas, N. Djebli, D. Fabre, 2018, Clinical Pharmacokinetics.

Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model—Support for a Biologics License Application Submission: Part I

D. Fabre, F. Hurbin, Jean-Marie Martinez, 2018, Clinical Pharmacokinetics.

Pharmacokinetics and Safety of a Single Oral Dose of Once‐Daily Alfuzosin, 10 mg, in Male Subjects with Mild to Severe Renal Impairment

T. Marbury, J. Pinquier, C. Rauch, 2002, Journal of clinical pharmacology.

Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients

S. Khier, D. Fabre, Jean-Marie Martinez, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacokinetics of new testosterone transdermal therapeutic systems in gonadotropin-releasing hormone antagonist-suppressed normal men.

E. Nieschlag, C. Rolf, H. Behre, 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.

H. Hachad, R. Levy, I. Ragueneau-Majlessi, 2007, Current drug metabolism.

Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects.

P. Ahtoy, P. Chrétien, C. Rauch, 2002, International journal of clinical pharmacology and therapeutics.

Bioequivalence of 2 Pediatric Formulations of Fexofenadine Hydrochloride Oral Suspension.

C. Rauch, L. Lucio, M. Lhéritier-Barrand, 2023, Clinical pharmacology in drug development.